Evidence map›Paper›PMID 22573037›Full record

ArticleCell death & disease2012

Neither loss of Bik alone, nor combined loss of Bik and Noxa, accelerate murine lymphoma development or render lymphoma cells resistant to DNA damaging drugs.

L Happo, B Phipson, G K Smyth, A Strasser, C L Scott

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

L HappoMolecular Genetics of Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
B Phipson
G K Smyth
A Strasser
C L Scott
Walter and Eliza Hall Institute of Medical Research · AUUniversity of Melbourne · AU

Funding

ONCOGENE-INDUCED LEUKEMOGENESIS IN TRANSGENIC MICER01CA043540 · NCI · WALTER AND ELIZA HALL INST MEDICAL RES · PI CORY, SUZANNE · 1987 to 2009
$1.7M
MECHANISMS IN THE REGULATION OF APOPTOSISR01CA080188 · NCI · WALTER AND ELIZA HALL INST MEDICAL RES · PI ADAMS, JERRY M · 1999 to 2006
$1.1M
NCI NIH HHS CA 43540NCI NIH HHS CA 80188NCI NIH HHS R01 CA043540NCI NIH HHS R01 CA080188
6 · The paper itself

Abstract

The pro-apoptotic BH3-only protein, BIK, is widely expressed and although many critical functions in developmental or stress-induced death have been ascribed to this protein, mice lacking Bik display no overt abnormalities. It has been postulated that Bik can serve as a tumour suppressor, on the basis that its deficiency and loss of apoptotic function have been reported in many human cancers, including lymphoid malignancies. Evasion of apoptosis is a major factor contributing to c-Myc-induced tumour development, but despite this, we found that Bik deficiency did not accelerate Eμ-Myc-induced lymphomagenesis. Co-operation between BIK and NOXA, another BH3-only protein, has been previously described, and was attributed to their complementary binding specificities to distinct subsets of pro-survival BCL-2 family proteins. Nevertheless, combined deficiency of Bik and Noxa did not alter the onset of Eμ-Myc transgene induced lymphoma development. Moreover, although p53-mediated induction of Bik has been reported, neither Eμ-Myc/Bik(-/-) nor Eμ-Myc/Bik(-/-)Noxa(-/-) lymphomas were more resistant than control Eμ-Myc lymphomas to killing by DNA damaging drugs, either in vitro or in vivo. These results suggest that Bik, even in combination with Noxa, is not a potent suppressor of c-Myc-driven tumourigenesis or critical for chemotherapeutic drug-induced killing of Myc-driven tumours.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAntineoplastic AgentsApoptosisApoptosis Regulatory ProteinsCell Line, TumorDNA DamageDrug Resistance, NeoplasmEtoposideFemaleLymphomaMaleMiceMice, Inbred C57BLMice, KnockoutMitochondrial ProteinsAdaptor Proteins, Signal TransducingAntineoplastic AgentsApoptosis Regulatory ProteinsBik protein, mouseEtoposideMitochondrial ProteinsPmaip1 protein, mouseProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-mycTumor Suppressor Protein p53

Identifiers

PMID22573037
PMCPMC3366076
OpenAlexW2053081539

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.